Ipamorelin

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction: What Makes Ipamorelin Unique?

In anti-aging research, a few peptides consistently stand out, and Ipamorelin is one of them. Despite being only five amino acids long, it is one of the most selective agonists of the growth hormone secretagogue receptor (GHS-R). This selectivity makes ipamorelin a useful tool for studying the GH axis with limited cross-activity at other hormonal pathways.

Because of this precision, ipamorelin is often called the “gentle growth hormone–releasing peptide.” Compared to other secretagogues like sermorelin or GHRP-6, it targets the GH axis almost exclusively, making it especially useful in controlled research on growth hormone pathways.

Mechanism of Action: How Ipamorelin Works

Ipamorelin functions by binding to and activating the ghrelin receptor (GHS-R), found in the brain, liver, heart, and skeletal muscle. Its primary effect in the brain is to stimulate the pituitary gland to release stored growth hormone.

Unlike many other GHS-R agonists, ipamorelin does not meaningfully influence ACTH or prolactin levels, further confirming its reputation as a selective and well-tolerated peptide. With a short half-life of about 2 hours, its activity is cleared within 6 hours.

Ipamorelin and Aging: Restoring Youthful Physiology

Aging is marked by declines in bone density, muscle mass, memory, and hormonal balance. Ipamorelin research shows promise in counteracting these age-related changes.

One key pathway is bone health. Normally, osteoclasts break down bone while osteoblasts rebuild it. With age, this balance shifts toward breakdown, causing fragility and bone loss. Ipamorelin appears to restore balance by reducing excess osteoclast activity and supporting bone formation, thereby maintaining skeletal integrity.

Fat Loss and Body Composition

Studies in mice show it accelerates lipolysis (fat breakdown).

Interestingly, it also enhances insulin release, which favors nutrient storage. At first glance, this seems contradictory—but ipamorelin’s dual action ensures calories are more likely stored in muscle tissue rather than fat.

Ghrelin Receptor Signaling and Neuroplasticity

The ghrelin receptor (GHS-R) is strongly linked to neuroplasticity. Activation improves:

• Long-term potentiation (strength of neural connections)

• Dendritic spine density (number of neuron-to-neuron connections)

Strengthening Bone Density

In rat studies, ipamorelin increased bone formation fourfold and boosted total bone mineral content by ~75%. It also proved effective in models of glucocorticoid-induced bone loss.

Nociception Research Models

Ghrelin analogues, including ipamorelin, reduce inflammatory, neuropathic, and visceral pain. Recent studies examined GI pain hypersensitivity in animal models. Because gut pain and anxiety often overlap, ipamorelin may also help researchers explore the gut-brain connection.

Safety and Limitations

Animal studies show ipamorelin has a strong safety profile with minimal side effects.

Molecular Structure of Ipamorelin

Structurally, ipamorelin is a short pentapeptide, engineered for selectivity and potency at the ghrelin receptor while minimizing cross-activity with other hormonal pathways.

REFERENCES

1. D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014.
2. B. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus,” J. Exp. Pharmacol., vol. 4, pp. 149–155, Oct. 2012.
3. M. M. Fowkes, T. Lalonde, L. Yu, S. Dhanvantari, M. S. Kovacs, and L. G. Luyt, “Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor,” Eur. J. Med. Chem., vol. 157, pp. 1500–1511, Sep. 2018.
4. A. Shimatsu, “[Ghrelin-related drugs: clinical perspectives],” Nihon Rinsho Jpn. J. Clin. Med., vol. 62 Suppl 9, pp. 435–438, Sep. 2004.
5. N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001.
6. J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000.
7. Y. Yin, Y. Li, and W. Zhang, “The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulation,” Int. J. Mol. Sci., vol. 15, no. 3, Art. no. 3, Mar. 2014, doi: 10.3390/ijms15034837.
8. V. Martínez Damonte, S. S. Rodríguez, and J. Raingo, “Growth hormone secretagogue receptor constitutive activity impairs voltage-gated calcium channel-dependent inhibitory neurotransmission in hippocampal neurons,” J. Physiol., vol. 596, no. 22, pp. 5415–5428, 2018, doi: 10.1113/JP276256.
9. E. N Mohammadi, T. Louwies, C. Pietra, S. R. Northrup, and B. Greenwood-Van Meerveld, “Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics,” J. Exp. Pharmacol., vol. 12, pp. 267–274, 2020, doi: 10.2147/JEP.S249747.

Product available for research use only: